|
BN003
|
-
|
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
|
|
BN009
|
-
|
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity
>=4 Brain Metastases/Year
Closed on 08/15/2024
|
|
BN010
|
-
|
A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE EFFICACY, SAFETY, AND IMPACT ON THE TUMOR MICROENVIRONMENT OF THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA
|
|
BN011
|
-
|
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
|
|
BN012
|
-
|
A RANDOMIZED PHASE III TRIAL OF PRE-OPERATIVE COMPARED TO POST-OPERATIVE STEREOTACTIC RADIO SURGERY IN PATIENTS WITH RESECTABLE BRAIN METASTASES.
|
|
BN013
|
-
|
PHASE III TRIAL OF SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) VERSUS FRACTIONATED SRS (FSRS) FOR INTACT BRAIN METASTASES
|
|
BN014
|
-
|
A PHASE III RANDOMIZED CLINICAL TRIAL OF PROTON CRANIOSPINAL IRRADIATION VERSUS INVOLVED-FIELD RADIOTHERAPY FOR PATIENTS WITH BREAST CANCER OR NON-SMALL CELL LUNG CANCER LEPTOMENINGEAL METASTASIS (RADIATE-LM)
|
|
BR007
|
-
|
A PHASE III CLINICAL TRIAL EVALUATING DEESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER
|
|
BR008
|
-
|
A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer” (HERO*)
|
|
CC009
|
-
|
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
|
|
CC013
|
-
|
A RANDOMIZED, MASKED, PLACEBO CONTROLLED, PHASE II TRIAL OF CONCURRENT CHEMORADIATION WITH BMX-001 IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA RECEIVING CONCURRENT CHEMORADIATION
|
|
DT001
|
-
|
A PHASE IB TRIAL OF NEOADJUVANT AMG 232 CONCURRENT WITH PREOPERATIVE RADIOTHERAPY IN WILD-TYPE P53 SOFT TISSUE SARCOMA (STS)
Cohort B closed
|
|
GI003
|
-
|
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
|
|
GI006
|
-
|
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
|
|
GU002
|
-
|
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
|
|
GU005
|
-
|
PHASE III IGRT AND SBRT VS IGRT AND HYPOFRACTIONATED IMRT FOR LOCALIZED INTERMEDIATE RISK PROSTATE CANCER
|
|
GU007
|
-
|
RANDOMIZED PHASE II TRIAL OF NIRAPARIB WITH STANDARD COMBINATION RADIOTHERAPY AND ANDROGEN DEPRIVATION THERAPY (ADT) IN HIGH RISK PROSTATE CANCER (WITH INITIAL PHASE I)
-- Temporarily closed on 08/01/2023
|
|
GU008
|
-
|
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
|
|
GU009
|
-
|
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)
|
|
GU010
|
-
|
PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC-RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENFISIFCATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)
|
|
GU011
|
-
|
A PHASE II DOUBLE-BLINDED,PLACEBO-CONTROLLED TRIAL OF PROSTATE OLIGOMETASTATIC RADIOTHERAPY WITH OR WITHOUT ANDROGEN DEPRIVATION THERAPY IN OLIGOMETASTATIC PROSTATE CANCER(NRO PROMETHEAN)
|
|
GU012
|
-
|
RANDOMIZED PHASE II STEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR METASTATIC UNRESECTED RENAL CELL CARCINOMA (RCC) RECEIVING IMMUNOTHERAPY
|
|
GU013
|
-
|
THE PHASE III 'HIGH FIVE TRIAL' FIVE FRACTION RADIATION FOR HIGH-RISK PROSTRATE CANCER.
|
|
GY017
|
-
|
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer--Temporarily closed
|
|
GY020
|
-
|
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
|
|
GY024
|
-
|
NRG ONCOLOGY PARTICIPATION APPENDIX GRONINGEN INTERNATIONAL STUDY ON SENTINEL NODES IN VULVAR CANCER (GROINSS-V) III: A PROSPECTIVE PHASE II TREATMENT TRIAL
|
|
HN005
|
-
|
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Temporarily closed as of 02/03/2023
|
|
HN006
|
-
|
RANDOMIZED PHASE II/III TRIAL OF SENTINEL LYMPH NODE BIOPSY VERSUS ELECTIVE NECK DISSECTION FOR EARLY-STAGE ORAL CAVITY CANCER
|
|
HN009
|
-
|
RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH HIGH-DOSE CISPLATIN (100 MG/M2) EVERY THREE WEEKS VERSUS RADIATION WITH LOW-DOSE WEEKLY CISPLATIN (40 MG/M2) FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
|
|
HN014
|
-
|
RANDOMIZED PHASE III TRIAL OF NEOADJUVANT IMMUNOTHERAPY WITH RESPONSE-ADAPTED TREATMENT VERSUS STANDARD-OF-CARE TREATMENT FOR RESECTABLE STAGE III/IV CUTANEOUS SQUAMOUS CELL CARCINOMA
|
|
LU007
|
-
|
Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
|
|
LU008
|
-
|
PHASE III PROSPECTIVE RANDOMIZED TRIAL OF PRIMARY LUNG TUMOR STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY CONCURRENT MEDIASTINAL CHEMORADIATION FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
|
|
SWOG/NRG 1806
|
-
|
Phase III Randomized Trial of Concurrent Chemotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
|
|
|